| 书目名称 | Druggable Lipid Signaling Pathways | | 编辑 | Yasuyuki Kihara | | 视频video | | | 概述 | Revisits historical achievements of lipid research and updates the latest understanding of lipid functions.Inspires new perspectives on discovering drugs in lipid signaling pathways.Written by the nex | | 丛书名称 | Advances in Experimental Medicine and Biology | | 图书封面 |  | | 描述 | .Lipids are responsible not just for constituting cellular membrane but also for storing energy, transducing signaling, and modifying proteins. Bioactive lipids, or lipid mediators, transduce signaling as intracellular messenger like phosphoinoitides, and also regulate cell-cell communication through G protein-coupled receptors (GPCRs) that are potentially valuable drug targets in many diseases. Until now, about 40 GPCRs within ~300 rhodopsin-like (class A) GPCRs, are identified as lipid GPCRs. Advances of lipid research have enabled to develop novel small molecules targeting lipid GPCRs for several diseases. Most notably, fingolimod (FTY720), a sphingosine 1-phosphate (S1P) receptor modulator, became the first FDA-approved medicine as an orally bioavailable drug for treating relapsing forms of multiple sclerosis (MS). In addition to fingolimod, other drugs targeting lipid GPCRs had been developed such as latanoprost (prostaglandin F2a analogue, used for ocular hypertension and glaucoma), epoprostenol and treprostinil (prostaglandin I2 analogue, used for pulmonary arterial hypertension), montelukast and pranlukast (cysteinyl leukotriene receptor antagonist, used for asthma and alle | | 出版日期 | Book 2020 | | 关键词 | lipids; GPCR; drug discovery; disease; translational research | | 版次 | 1 | | doi | https://doi.org/10.1007/978-3-030-50621-6 | | isbn_softcover | 978-3-030-50623-0 | | isbn_ebook | 978-3-030-50621-6Series ISSN 0065-2598 Series E-ISSN 2214-8019 | | issn_series | 0065-2598 | | copyright | Springer Nature Switzerland AG 2020 |
The information of publication is updating
|
|
发表于 2025-3-21 18:52:45
